![]() ![]() ![]() Here are two very widely listened to, highly respected programs suggesting the use of idarucizumab. Their conclusion is a little less glowing, but the end result is the same: “The best evidence to date – and I’m not saying it’s great – but the best evidence is to use idarucizumab.” There is some great stuff in there, but then they talked about idarucizumab. If you don’t have it, get it, and if you do have it start using it.” That’s a pretty glowing review, but unfortunately it’s dead wrong.Īround the same time, Emergency Medicine Cases released an (overall excellent) episode on the management of intracerebral hemorrhage with Dr. Idarucizumab is here, it works, it’s safe. In the January 2018 EM:RAP, the paper chase segment gave us a fairly uncritical look at the one big study “supporting” the use of idarucizumab. But in this instance, I think that they were both wrong. ![]() Walter Himmel, who is one of the smartest individuals I have ever had the opportunity to meet. On EM Cases, the statements were made by Dr. EM:RAP has been irreplaceable in my emergency medicine education. I have incredible respect for these sources. This month I was distressed to hear overly-optimistic, unscientific statements about idarucizumab on two of my favourite emergency medicine education programs: EM:RAP and EM Cases. As physicians, we cannot afford optimism blindness. Optimism, however, can cloud also cloud our judgement allow us to focus only on the good, not the bad. When facing an onslaught of critically ill patients, optimism allows emergency physicians to persist. Few things are as powerful as hope for the future. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |